The reason for regeneration in the adult spinal cord during motor neuron degeneration in amyotrophic lateral sclerosis (ALS) remains largely unknown. To this end, we studied the alteration of vimentin (a neural precursor cells marker in CNS)-containing cells (VCCs) in spinal cord during different stages of ALS used C57BL/6J G93A SOD1 transgenic mice mimicking ALS. Results showed that VCCs were mostly distributed in the ependymal zone (EZ) surrounding the central canal of spinal cord in SOD1 wild type mice; a few of VCCs were sparsely distributed in other regions. However, the number of VCCs significantly increased in the spinal cord during the onset and progression stages of ALS. They were extensively distributed in the EZ, the anterior, the lateral and the posterior horn of grey matter, particularly in the posterior horn region at the progression stage. A majority of VCCs in the anterior, the lateral and the posterior horn of grey matter (outside of EZ) generated astrocytes, but no neurons, oligodendrocytes and microgliocytes. Our results suggested that there was a potential astrocyte regenerative response to motor neuron degeneration in motor neurons-degenerated regions in the adult spinal cord during the onset and progression stages of ALS-like disease. The regenerative responses in the adult spinal cord of ALS-like mice may be a potential pathway in attempting to repair the degenerated motor neurons and restore the dysfunctional neural circuitry.

Keywords:
Amyotrophic lateral sclerosis, Vimentin, Astrocyte, Astrogenesis, Neural precursor cells
1.
Mitchell JD, Borasio GD: Amyotrophic lateral sclerosis. Lancet 2007;369:2031-2041.
2.
Wijesekera LC, Leigh PN: Amyotrophic lateral sclerosis. Orphanet J Rare Dis 1994;4:3.
3.
Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, O'Regan JP, Deng HX, et al: Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993;362:59-62.
4.
Contestabile A: Amyotrophic lateral sclerosis: from research to therapeutic attempts and therapeutic perspectives. Curr Med Chem 2011;18:5655-5665.
5.
Liscic RM, Breljak D: Molecular basis of amyotrophic lateral sclerosis. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:370-372.
6.
Traub R, Mitsumoto H, Rowland LP: Research advances in amyotrophic lateral sclerosis, 2009 to 2010. Curr Neurol Neurosci Rep 2011;11:67-77.
7.
Cheah BC, Vucic S, Krishnan AV, Kiernan MC: Riluzole, neuroprotection and amyotrophic lateral sclerosis. Curr Med Chem 2010;17:1942-1999.
8.
Lindvall O, Kokaia Z: Stem cells in human neurodegenerative disorders - time for clinical translation? J Clin Invest 2010;120:29-40.
9.
Chi L, Ke Y, Luo C, Li B, Gozal D, Kalyanaraman B, Liu R: Motor neuron degeneration promotes neural progenitor cell proliferation, migration, and neurogenesis in the spinal cords of amyotrophic lateral sclerosis mice. Stem Cells 2006;24:34-43.
10.
Chi L, Gan L, Luo C, Lien L, Liu R: Temporal response of neural progenitor cells to disease onset and progression in amyotrophic lateral sclerosis-like transgenic mice. Stem Cells Dev 2007;16:579-588.
11.
Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, Caliendo J, Hentati A, Kwon YW, Deng HX, et al: Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 1994;264:1772-1775.
12.
Henriques A, Pitzer C, Schneider A: Characterization of a novel SOD-1(G93A) transgenic mouse line with very decelerated disease development. PLoS One 2010;5:e15445.
13.
Lazarides E: Intermediate filaments: a chemically heterogeneous, developmentally regulated class of proteins. Annu Rev Biochem 1982;51:219-250.
14.
Steinert PM, Steven AC, Roop DR: The molecular biology of intermediate filaments. Cell 1985;42:411-420.
15.
Fuchs E, Cleveland DW: A structural scaffolding of intermediate filaments in health and disease. Science 1998;279:514-519.
16.
Eng LF, Ghirnikar RS: GFAP and astrogliosis. Brain Pathol 1994;4:229-237.
17.
Frisén J, Johansson CB, Török C, Risling M, Lendahl U: Rapid, widespread, and longlasting induction of nestin contributes to the generation of glial scar tissue after CNS injury. J Cell Biol 1995;131:453-464.
18.
Matsuda Y, Yoshimura H, Suzuki T, Ishiwata T: Nestin: Neural Stem/Progenitor Cell Marker in Brain Tumors; in Lichtor T (ed): Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications. InTech, Chapter 23, 2013.
19.
Hockfield S, McKay RD: Identification of major cell classes in the developing mammalian nervous system. J Neurosci 1985;5:3310-3328.
20.
Zimmerman L, Parr B, Lendahl U, Cunningham M, McKay R, Gavin B, Mann J, Vassileva G, McMahon A: Independent regulatory elements in the nestin gene direct transgene expression to neural stem cells or muscle precursors. Neuron 1994;12:11-24.
21.
Wiese C, Rolletschek A, Kania G, Blyszczuk P, Tarasov KV, Tarasova Y, Wersto RP, Boheler KR, Wobus AM: Nestin expression - a property of multi-lineage progenitor cells? Cell Mol Life Sci 2004;61:2510-2522.
22.
Lendahl U, Zimmerman LB, McKay RD: CNS stem cells express a new class of intermediate filament protein. Cell 1990;60:585-595.
23.
Li L, Mignone J, Yang M, Matic M, Penman S, Enikolopov G, Hoffman RM: Nestin expression in hair follicle sheath progenitor cells. Proc Natl Acad Sci U S A 2003;100:9958-9961.
24.
Walder S, Ferretti P: Distinct neural precursors in the developing human spinal cord. Int J Dev Biol 2004;48:671-674.
25.
Liu Z, Martin LJ: The adult neural stem and progenitor cell niche is altered in amyotrophic lateral sclerosis mouse brain. J Comp Neurol 2006;497:468-488.
26.
Rasmussen MA, Hall VJ, Carter TF, Hyttel P: Directed differentiation of porcine epiblast-derived neural progenitor cells into neurons and glia. Stem Cell Res 2011;7:124-136.
27.
Cordero-Llana O, Scott SA, Maslen SL, Anderson JM, Boyle J, Chowhdury RR, Tyers P, Barker RA, Kelly CM, Rosser AE, et al: Clusterin secreted by astrocytes enhances neuronal differentiation from human neural precursor cells. Cell Death Differ 2011;18:907-913.
28.
Gao Y, Jammes H, Rasmussen MA, Oestrup O, Beaujean N, Hall V, Hyttel P: Epigenetic regulation of gene expression in porcine epiblast, hypoblast, trophectoderm and epiblast-derived neural progenitor cells. Epigenetics 2011;6:1149-1161.
29.
Eng LF, Ghirnikar RS, Lee YL: Glial fibrillary acidic protein: GFAP-thirty-one years (1969-2000). Neurochem Res 2000;25:1439-1451.
30.
Widestrand A, Faijerson J, Wilhelmsson U, Smith PL, Li L, Sihlbom C, Eriksson PS, Pekny M: Increased neurogenesis and astrogenesis from neural progenitor cells grafted in the hippocampus of GFAP-/- Vim-/- mice. Stem Cells 2007;25:2619-2627.
31.
Dahl D, Rueger DC, Bignami A, Weber K, Osborn M: Vimentin, the 57 000 molecular weight protein of fibroblast filaments, is the major cytoskeletal component in immature glia. Eur J Cell Biol 1981;24:191-196.
32.
Bignami A, Raju T, Dahl D: Localization of vimentin, the nonspecific intermediate filament protein, in embryonal glia and in early differentiating neurons. In vivo and in vitro immunofluorescence study of the rat embryo with vimentin and neurofilament antisera. Dev Biol 1982;91:286-295.
33.
Bodega G, Suárez I, Rubio M, Fernández B: Ependyma: phylogenetic evolution of gial fibrillary acidic protein (GFAP) and vimentin expression in vertebrate spinal cord. Histochemistry 1994;102:113-122.
34.
Kamei Y, Inagaki N, Nishizawa M, Tsutsumi O, Taketani Y, Inagaki M: Visualization of mitotic radial glial lineage cells in the developing rat brain by Cdc2 kinase-phosphorylated vimentin. Glia 1998;23:191-199.
35.
Nieminen M, Henttinen T, Merinen M, Marttila-Ichihara F, Eriksson JE, Jalkanen S: Vimentin function in lymphocyte adhesion and transcellular migration. Nat Cell Biol 2006;8:156-162.
36.
Mendez MG, Kojima S, Goldman RD: Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition. FASEB J 2010;24:1838-1851.
37.
Ivaska J: Vimentin: central hub in EMT induction? Small GTPases 2011;2:51-53.
38.
Hay ED: The mesenchymal cell, its role in the embryo, and the remarkable signaling mechanisms that create it. Dev Dyn 2005;233:706-720.
39.
Abbott NJ: Developmental neurobiology. The milieu is the message. Nature 1998;332:490-491.
40.
Allaman I, Bélanger M, Magistretti PJ: Astrocyte-neuron metabolic relationships: for better and for worse. Trends Neurosci 2011;34:76-87.
41.
Lie DC, Colamarino SA, Song HJ, Désiré L, Mira H, Consiglio A, Lein ES, Jessberger S, Lansford H, Dearie AR, Gage FH: Wnt signalling regulates adult hippocampal neurogenesis. Nature 2005;437:1370-1375.
42.
Okamoto M, Inoue K, Iwamura H, Terashima K, Soya H, Asashima M, Kuwabara T: Reduction in paracrine Wnt3 factors during aging causes impaired adult neurogenesis. FASEB J 2011;25:3570-3582.
43.
Takano T, Tian GF, Peng W, Lou N, Libionka W, Han X, Nedergaard M: Astrocyte-mediated control of cerebral blood flow. Nat Neurosci 2006;9:260-267.
44.
Bernardinelli Y, Salmon C, Jones EV, Farmer WT, Stellwagen D, Murai KK: Astrocytes display complex and localized calcium responses to single-neuron stimulation in the hippocampus. J Neurosci 2011;31:8905-8919.
45.
Panatier A, Vallee J, Haber M, Murai KK, Lacaille JC, Robitaille R: Astrocytes are endogenous regulators of basal transmission at central synapses. Cell 2011;146:785-798.
46.
David S, Aguayo AJ: Axonal elongation into peripheral nervous system ‘bridges' after central nervous system injury in adult rats. Science 1981;214:931-933.
47.
Reier PJ, Eng LF, Jakeman L: Reactive astrocyte and axonal outgrowth in the injured CNS: is gliosis really an impediment to regeneration? In Seil FJ (ed): Neural Regeneration and Transplantation. Alan Lis, New York, 1989, pp 183-209.
48.
Bignami A, Dahl D: The astroglial response to stabbing. Immunofluorescence studies with antibodies to astrocyte specific protein (GFA) in mammalian and submammalian vertebrates. Neuropath Appl Neurobiol 1976;2:99-110.
49.
Bignami A, Eng LF, Dahl D, Uyeda CT: Localization of the glial fibrillary acidic protein in astrocytes by immunofluorescence. Brain Res 1972;43:429-435.
50.
Clarke SR, Shetty AK, Bradley JL, Turner DA: Reactive astrocytes express the embryonic intermediate neurofilament nestin. Neuroreport 1994;5:1885-1888.
51.
Lin RC, Matesic DF, Marvin M, McKay RD, Brüstle O: Re-expression of the intermediate filament nestin in reactive astrocytes. Neurobiol Dis 1995;2:79-85.
52.
Divya MS, Roshin GE, Divya TS, Rasheed VA, Santhoshkumar TR, Elizabeth KE, James J, Pillai RM: Umbilical cord blood-derived mesenchymal stem cells consist of a unique population of progenitors co-expressing mesenchymal stem cell and neuronal markers capable of instantaneous neuronal differentiation. Stem Cell Res Ther 2012;3:57.
53.
Choi MR, Kim HY, Park JY, Lee TY, Baik CS, Chai YG, Jung KH, Park KS, Roh W, Kim KS, Kim SH: Selection of optimal passage of bone marrow-derived mesenchymal stem cells for stem cell therapy in patients with amyotrophic lateral sclerosis. Neurosci Lett 2010;472:94-98.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.